Targeted therapy outcomes in RET-rearranged lung cancers: drug or driver?

Lancet Respir Med. 2017 Jan;5(1):5-6. doi: 10.1016/S2213-2600(16)30369-1. Epub 2016 Nov 4.

Author

Alexander Drilon¹

Affiliation

¹ Thoracic Oncology Service and Developmental Therapeutics Clinic, Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine, New York, NY 10065, USA. Electronic address: drilona@mskcc.org.

PMID: 27825615
DOI: 10.1016/S2213-2600(16)30369-1

No abstract available

Publication types

Comment

MeSH terms

Adenocarcinoma
Carcinoma, Non-Small-Cell Lung*
Humans
Lung Neoplasms*
Proto-Oncogene Proteins c-ret

Substances

Proto-Oncogene Proteins c-ret
RET protein, human